Enflamen
On sale on the US market (according to the DSLD)
Patient One 1 MediNutritionals, food supplement from the US market
Enflamen (Patient One 1 MediNutritionals), a food supplement au code-barres 853959004328, is described by its US market label. If sold in France, it would be subject to 2 points of French or European regulation, detailed below. The formula sold in Europe under the same name may differ.
Official label. Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels, retrieved 27 October 2026.
Source: NIH Office of Dietary Supplements, Dietary Supplement Label Database (CC0); US market labels.
If this product were sold in France
- Legal conditions
Contains tea (Camellia sinensis). Green tea extracts must provide less than 800 mg of epigallocatechin-3-gallate per daily portion, with mandatory warnings.
Source: Regulation (EC) No 1925/2006, latest consolidated version, annexe III, partie B (règlement (UE) 2022/2340).
- Legal conditions
Camellia sinensis (L.) Kuntze: Seules sont admises la poudre issue du broyage des feuilles et les préparations obtenues à partir des solvants suivants : l'eau, l'alcool à 25 % (v/v), ainsi que les solvants autorisés pour la décaféination ou la suppression des matières irritantes et amères. Les recommandations d'emploi ne doivent pas conduire à une ingestion quotidienne d'EGCG supérieure à 300 mg. L'étiquetage doit comporter des avertissements déconseillant leur prise en dehors des repas, ainsi que leur consommation par les enfants, les adolescents, les femmes enceintes ou allaitantes.
Source: French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, arrêté du 24 juin 2014, annexe I.
A daily dose is calculated only if the label gives the maximum number of servings and a unit of mass (or international units for vitamin D). Quantities come from the label, not an analysis. In the United States, the label presents this product as a ‘dietary supplement’; in France, a product of this type may belong to another category (a sports powder, for example), and maximum food supplement doses do not apply to it.
Label composition
- Brand
- Patient One 1 MediNutritionals
- Barcode
- 853959004328
- Form
- Capsule
- One serving
- 3 capsules
- Servings
- up to 1 serving per day
- Other ingredients (in English, as written)
- Vegetable Cellulose, Chlorophyll
| Ingredient (as written, in English) | Category | Per serving |
|---|---|---|
| Calories | Other | 13 Calorie(s) |
| Total Fat | Fat | 1 Gram(s) |
| Saturated Fat | Fat | 0.2 Gram(s) |
| Monounsaturated Fat | Fat | 0.2 Gram(s) |
| Polyunsaturated Fat | Fat | 0.6 Gram(s) |
| Total Carbohydrates | Carbohydrate | 0.5 Gram(s) |
| Other Carbohydrates | Carbohydrate | 0.5 Gram(s) |
| Omega 3 Fish Oil | Fat | 1,000 mg |
| D-Limonene | Other substance | 250 mg |
| Rosemary extract | Plant | 100 mg |
| Meriva Phytosome Turmeric Complex | Other substance | 100 mg |
| Ashwagandha extract (Withania somnifera) | Plant | 50 mg |
| Barberry extract | Plant | 25 mg |
| Black Cumin Oil | Fat | 25 mg |
| Boswellin Boswellia serrata (resin) extract | Plant | 50 mg |
| Bromelain | Enzyme | 25 mg |
| Capsimax Capsicum extract (Capsicum annuum) | Plant | 25 mg |
| Coptis chinensis extract | Plant | 25 mg |
| Ginger root extract | Plant | 100 mg |
| Holy Basil extract | Plant | 100 mg |
| Green Tea extract (Camellia sinensis) | Plant | 100 mg |
| Polygonum cuspidatum extract | Plant | 25 mg |
| Oregano 4:1 extract | Plant | 25 mg |
| Scullcap herb powder | Plant | 25 mg |
Displayed label: Official label. Labels on the market are prioritised, followed by the most recent for the same status.
Other versions of this label
The differences below describe each other version relative to the label shown on this page. They concern active ingredient rows and quantities per serving as written. Missing quantities are not estimated and different units are not converted. Dates refer to entry into DSLD, not necessarily to a formula change.
Official label: Enflamen
Entered into DSLD on 23 August 2019. Withdrawn from the US market on 26 March 2021 (according to the DSLD).Same active composition.
Official label: Enflamen
Entered into DSLD on 25 August 2015. Withdrawn from the US market on 28 February 2019 (according to the DSLD).- Active ingredient added : Calories from Fat (10 {Calories})
- Active ingredient added : Curcuma longa (quantity not stated)
- Active ingredient added : Glycine max Soybeans (quantity not stated)
- Same quantity, different name: Meriva(R) Turmeric Phytosome(TM) in this version; Meriva Phytosome Turmeric Complex on the displayed label (100 mg)
- Same quantity, different name: Skullcap herb powder in this version; Scullcap herb powder on the displayed label (25 mg)
- Different unit, without conversion : Calories: 13 {Calories} in this version; 13 Calorie(s) on the displayed label
This information reproduces the US label recorded by the US National Institutes of Health (NIH). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.
Official warnings (Health Canada)
Health Canada publishes warnings on these ingredients:
- Ashwagandha extract
Read the warning, when it applies and the studies cited
ASHWAGANDHA - WITHANIA SOMNIFERA
Route of administration: Oral
Cautions and warnings
Condition of application: General debility; Memory enhancement; Adaptogen; Restlessness/nervousness.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Condition of application: All products.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Upton 2000; McGuffin et al. 1997).
Sources cited by Health Canada (3)
- McGuffin M, Hobbs C, Upton R, Goldberg A, editors. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL): CRC Press, LLC; 1997.
- Upton R, editor. American Herbal Pharmacopoeia and Therapeutic Compendium: Ashwagandha Root (Withania somnifera) - Standards of Analysis, Quality Control, and Therapeutics. Santa Cruz (CA): American Herbal Pharmacopoeia; 2000.
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze K, éditeurs. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13e édition. Washington (DC) : American Pharmaceutical Association; 2002.
When using this product exercise caution if you drive or use machinery as you may experience drowsiness (Berardi et al. 2002).
Sources cited by Health Canada (3)
- Berardi RR, DeSimone EM, Newton GD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA and Tietze KJ, editors. Handbook of Nonprescription Drugs: An Interactive Approach to Self-Care, 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- McGuffin M, Hobbs C, Upton R, Goldberg A, éditeurs. American Herbal Products Association's Botanical Safety Handbook. Boca Raton (FL) : CRC Press, LLC; 1997.
- Upton R, éditeur. Ashwagandha Root, Withania somnifera Analytical, Quality Control, And Therapeutic Monograph. Santa Cruz (CA) : American Herbal Pharmacopoeia and Therapeutic Compendium; 2000.
- Capsimax Capsicum extract
Read the warning, when it applies and the studies cited
CAYENNE - CAPSICUM ANNUUM Oral
Cautions and warnings
Condition of application: All products.
Keep out of the reach of children. If overdose or accidental ingestion occurs, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are pregnant or breastfeeding (Bradley 2006; Boon and Smith 2004).
Sources cited by Health Canada (2)
- Boon H, Smith MJ. The Complete Natural Medicine Guide to the 50 Most Common Medicinal Herbs, 2nd edition. Toronto (ON): Robert Rose Inc; 2004.
- Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 2. Bournemouth (GB): British Herbal Medicine Association; 2006.
Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you have stomach ulcers or inflammation (Brinker 2010).
Sources cited by Health Canada (1)
- Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
Condition of application: Digestion; Peripheral circulation.
Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.
Health Canada monograph dated 27 March 2026
CAYENNE - CAPSICUM ANNUUM/CAPSAICIN Topical
Cautions and warnings
Condition of application: All products.
For external use only (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
When using this product avoid contact with the eyes and mucous membranes. If contact occurs, rinse thoroughly with water (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Stop use and ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist, worsen, or re-occur within a few days (US FDA 2023).
Sources cited by Health Canada (1)
- US FDA 2023: United States Food and Drug Administration. Over-the-Counter Monograph M017: External Analgesics Drug Products for Over-the-Counter Human Use. Washington (DC): U.S. Food and Drug Administration, Department of Health and Human Services. [Accessed 2026 February 27]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/omuf/monographs/OTC%20Monograph_M017-External%20Analgesic%20Drug%20Products%20for%20OTC%20Human%20Use%2005.02.2023.pdf
1 study cited in the text has no matching reference in the monograph (see the anomalies listed on the sources page).
Keep out of the reach of children. If swallowed, call a poison control centre or get medical help right away (CPS 2008).
Sources cited by Health Canada (1)
- CPS 2008: Repchinksy C, Welbanks L, Bhalla A, Fortin K, Jarvis B, Jovaisas B, Acharya S. Compendium of Pharmaceutical Specialties. Ottawa (ON): Canadian Pharmacists Association; 2008.
Known adverse reactions
Condition of application: All products.
Stop use if headache, redness, rashes, burning discomfort and/or hypersensitivity occur (Brayfield and Cadart 2024; Zhang et al. 2008; Hoffman 2003; APhA 2002; McCleane 2000).
Sources cited by Health Canada (5)
- APhA 2002: Berardi RR, DeSimone EM, Newton GGD, Oszko MA, Popovich NG, Rollins CJ, Shimp LA, Tietze KJ, editors. Handbook of Nonprescription Drugs: An interactive approach to self-care. 13th edition. Washington (DC): American Pharmaceutical Association; 2002.
- Brayfield A, Cadart C, editors. Martindale: The Complete Drug Reference. London (GB): Pharmaceutical Press; 2024. [Accessed 2024 August 14]. Available from: https://www.medicinescomplete.com/#/browse/martindale
- Hoffman D. Medical Herbalism: The Science and Practice of Herbal Medicine. Rochester (VT): Healing Arts Press; 2003.
- McCleane G. Topical application of doxepin hydrochloride, capsaicin and a combination of both produces analgesia in chronic human neuropathic pain: a randomized, double-blind, placebo-controlled study. British Journal of Clinical Pharmacology 2000;49:574-579. PubMed Randomised trial
- Zhang W, Moskowitz, RW, Nuki G, Abramson S, Altman RD, Arden N, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis and Cartilage 2008;16:137-162. PubMed Systematic review
They concern the ingredient, not this product or its dose. They do not replace medical advice.
List declared on (register: Dietary Supplement Label Database (DSLD), US National Institutes of Health: current and off-market labels).
Brand : Patient One 1 MediNutritionals
Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.
Cite this page: CompoAtlas, “Enflamen (Patient One 1 MediNutritionals): composition and French regulation”, https://compoatlas.com/en/supplements/us-labels/853959004328-enflamen-patient-one-1-medinutritionals, updated 22 May 2021.